Salix teams up with Crohn's & Colitis Foundation of America for this year's
Take Steps event
KANSAS CITY, Mo., June 12 /PRNewswire/ -- The Crohn's & Colitis Foundation of America (CCFA) is happy to announce that Salix Pharmaceuticals, a leader in gastroenterology, is a major sponsor of this year's Take Steps event on June 14th at 4 p.m. starting with family festivities in Overland Park, Kansas a suburb of Kansas City. The 5K walk begins after the festivities at 7 PM and takes place at Corporate Woods Office Park and is expected to draw hundreds of participants who will carry noisemakers to break the silence when it comes to Crohn's disease and ulcerative colitis.
While Takes Steps for Crohn's & Colitis events are taking place in dozen of cities around the country this year, Salix has selected Kansas City as one of only four markets in which to be a major sponsor.
"We work closely with the CCFA to support its overall mission nationwide. In addition, CCFA conducts many local, awareness-building events around the country and we have chosen Kansas City as a pilot market for supporting CCFA's local activities," says Mike Freeman, Executive Director, Investor Relations & Corporate Communications. "We want patients in Indianapolis to know that they have a choice in bowel preparations and may not necessarily have to drink large amounts of unpleasant-tasting liquids when they prepare for their colonoscopies."
Approximately 70,000 people in the Kansas City Metro area and nearly 1.5 million Americans have Crohn's disease or ulcerative colitis. More than 83 cents of every dollar raised from Take Steps directly supports The Crohn's & Colitis Foundation's research, education and support initiatives. This event, however, not only raises money for Crohn's disease and colitis research, but it also brings about awareness of these two painful and unpredictable afflictions.
Andi Harrington, development manager for the Mid-America Chapter of the Crohn's & Colitis Foundation of America, is thrilled to have a national pharmaceutical company taking part in this year's event. "To have Salix sponsor the local Take Steps event and choose Kansas City is a great honor for us and the city. We're happy to be partnering with a company that develops and provides innovative treatment options for patients with inflammatory bowel disease that undergo colonoscopies on a regular basis."
Take Steps for Crohn's & Colitis is the nation's largest event dedicated to finding cures for digestive diseases. Participants raise money for crucial research that wouldn't even have been possible a few short years ago, bringing us closer to a future free from Crohn's disease and ulcerative colitis. Beyond raising money for research, Take Steps brings together the Crohn's and colitis community in a fun and energetic atmosphere. Participants are encouraged to make noise and be heard -- raising awareness of these little -- known diseases in their community and across the nation.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix markets COLAZAL(R) (balsalazide disodium) Capsules 750 mg, XIFAXAN(R) (rifaximin) tablets 200 mg , OSMOPREP(R) (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets, MOVIPREP(R) (PEG 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral Solution), VISICOL(R) (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets, PEPCID(R) (famotidine) for Oral Suspension, Oral Suspension DIURIL(R) (Chlorothiazide), AZASAN(R) Azathioprine Tablets, USP, 75/100 mg , ANUSOL-HC(R) 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC(R) 25 mg Suppository (Hydrocortisone Acetate), PROCTOCORT(R) Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT(R) Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 mg. Vapreotide acetate, balsalazide tablet, granulated mesalamine and XIFAXAN(R) for additional indications are under development.
|SOURCE Salix Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved